Shanghai Medicilon Inc.

  On July 14, the IND application for the BIOT-001 project targeting the S1P1 target declared by Biotime Biotechnology obtained the US FDA's clinical implied license and agreed to carry out phase I clinical trials. The indication is ulcerative colitis. Shanghai Medicilon Inc, as a strategic partner of Biotime Biotechnology, provided  preclinical R&D services  from  target  to  IND declaration  for the R&D of BIOT-001, and made every effort to complete the project with high quality and efficiency. BIOT-001 is an innovative small-molecule drug independently developed by Biotime Biotechnology with global intellectual property rights.  BIOT-001 is an orally active receptor agonist targeting S1P1.  Preclinical studies have shown that BIOT-001 can selectively bind to S1P receptor subtype 1 (S1P1) with high affinity, thereby inducing the isolation of peripheral blood lymphocytes, reducing the migration of activated circulating lymphocytes to the gastrointestinal tract, and has the

  Recently, Neologics Bioscience announced that its research and development pipeline NB002 for the treatment of solid tumors has successfully passed the review of the US FDA and agreed to conduct phase I clinical trials (IND number: 165196). Shanghai Medicilon Inc, as a partner of Neologics Bioscience, provided preclinical research services such as  safety evaluation  and  pharmacokinetics  for NB002, and assisted its IND application successfully obtain FDA clinical approval.  Novel humanized TIM-3 antibody NB002 is expected to open up a new path for tumor immunotherapy. NB002, independently developed by Neologics Bioscience, is a monoclonal therapeutic antibody targeting a unique epitope of TIM-3, which has a significant single-drug anti-tumor therapeutic effect.  It not only significantly activates the activity of T and NK cells and enhances their anti-tumor ability, but more importantly, NB002 rebuilds the suppressed innate immunity in the tumor environment, restores the ability of

  On June 28, Chuansha Park of Shanghai Medicilon Inc. (Medicilon) welcomed familiar customers - Dr. Yan Feng, Founder and CEO of Leading Tac Pharma, Dr. Juan XU, VP of Bioanalysis and Proteomics, and a group of colleagues.  This time, Dr. Feng Yan and his party visited Medicilon in person, just to award the   Medicilon DMPK team   the "Best Partner Award" to express their gratitude and recognition.  Professor Shuangqing Peng, Chief Scientific Officer of Medicilon, and Dr. Pin Jiang, Director of the Department of Pharmacokinetics and Bioanalysis, warmly received and had an fruitful discussion. During the symposium, the two parties actively interacted, offered suggestions, shared the latest scientific and technological achievements and R&D experience around their respective advantages and needs, discussed in depth the status quo, development trends of the biomedical industry, and project R&D strategies, and clarified the next step of the project's planning and depl

  On July 14, Professor Xiongwen Lu, Dean of the School of Management of Fudan University, led the professor group of Fudan School of Management and the students of the fifth phase of the Fudan Science and Technology Entrepreneur Camp into the Zhangjiang Park of Shanghai Medicilon Inc. (Medicilon) to conduct a site visit.  Dr. Chunlin Chen, the founder and CEO of Medicilon, and others gave a warm reception.  The two parties conducted in-depth exchanges and discussions on technological entrepreneurship, enterprise management, and industry development trends. In order to experience the development process of Medicilon, Dr. Chunlin Chen led the scientific and technological entrepreneurs to visit the Medicilon cultural wall.   Dr. Chen introduced Medicilon has adhered to scientific and technological innovation since its establishment 19 years ago, benchmarked against international frontier fields, increased investment in research and development, and overcome key core technologies.  As a r

  On July 4th, the Press Conference of the 2022-2023 Most Influential List of China's Pharmaceutical Industry hosted by the All-China Federation of Industry and Commerce, Pharmaceutical Industry Chamber of Commerce was held in Harbin.  The press conference released the most influential list of China's pharmaceutical industry in 2022-2023.   Medicilon once again won the "Top 50 Chinese Pharmaceutical R&D" in 2022-2023 based on its comprehensive strength. The "Most Influential List of China's Pharmaceutical Industry" by the All-China Federation of Industry and Commerce (ACFIC), Pharmaceutical Chamber of Commerce has become one of the authoritative lists of Chinese pharmaceutical industry.  The ACFIC invited first-class Chinese experts to form a selection team.  The selection adheres to the principles of open collection, objective data, strict screening, and fair selection.  United with a number of well-known Chinese media, focusing on the comprehensiv

  On June 29, the 9th China Bio-Pharma Innovation Cooperation Conference (BIO-PHARM2023) and the 2023 China Biopharmaceutical Industry Value List Awards Ceremony were grandly opened in Suzhou.  Shanghai Medicilon Inc. was listed in the "Top 10 Most Influential CRO Enterprises" of the 2023 China Biopharmaceutical Industry Value List by virtue of its excellent R&D capabilities and outstanding innovative service platform. The Huayi List - 2023 China Biopharmaceutical Industry Value List is established by the Huayi Research Institute through selection, aiming to discover innovative companies with real industry influence and growth potential in the field of biopharmaceutical.  Huayi Research Institute is one of the few medical investment research institutes in China, and is also the definer of the China medical investment.  The value list consists of five series of selections:  antibody drugs , innovative therapies, biotechnology, CRO, and  CDMO , and the selection was based o

  Recently, Shanghai Medicilon Inc. (Medicilon) and EyeCure reached a strategic collaboration.  The two parties will carry out comprehensive collaboration in the field of ophthalmic cell and gene therapy. Since its establishment in 2015, EyeCure has been deeply involved in the field of ophthalmic cell and gene therapy.  Its research and development focus on the development of human retinal pigment epithelial cells, corneal cells and mesenchymal stem cells, creating a new therapeutic field of using adult RPE cells to treat age-related macular degeneration and pigmentary degeneration.  Medicilon, as a one-stop preclinical biopharmaceutical comprehensive R&D service CRO, has also been deeply involved in the field of ophthalmic drugs for many years, and has established the "Medicilon Preclinical Ophthalmic Drug Research Platform" which can provide efficient, high-quality, and cost-effective drug discovery, pharmaceutical research, preclinical research services. Medicilon Prec

On June 27, the 2022 China Pharmaceutical Industry Top 100 Series List was released.  Shanghai Medicilon Inc. was once again shortlisted in the "China CXO Enterprises Top 20 List". Being on the list for five consecutive times is a high affirmation and praise from industry authorities for the comprehensive strength of Medicilon's one-stop  biopharmaceutical preclinical R&D service platform .  It is also the recognition and encouragement of the sustainable development of Medicilon in the future! "China's Top 100 Pharmaceutical Industry List Series" is initiated and hosted by Menet.com.cn, a leading platform for China's pharmaceutical and health information.  It aims to set a benchmark for china pharmaceutical industry enterprises to enhance their comprehensive strength and expand brand effectiveness, demonstrate the excellence of the pharmaceutical brand industry, and guide the steady, rapid and sustainable development of the pharmaceutical and health

  Recently, Shanghai Medicilon Inc. (Medicilon) and SciMatchmaker reached a strategic collaboration.  The two parties have reached an agreement on collaboration in new drug research and development and resource sharing.  The joint advantages of the two sides complement each other.   Through continuous in-depth collaboration, they will open up new project potentials in new areas.  Through powerful system transformation services and proof-of-concept technologies to jointly promote the transformation from "science" to "technology", especially the industrialization of major basic research results, both parties will jointly assist in the verification, transformation, promotion and application of early scientific research results, and actively promote a deeply integrated technological innovation system. SciMatchmaker is committed to establish an all-ecological platform for the transfer and transformation of innovative medical scientific and technological achievements with

  Type 2 diabetes is a progressive disease. The disease course is primarily characterized by a decline in β-cell function and worsening of insulin resistance. Therefore, various antidiabetic agents are under research and development. The hypoglycemic strategy has also shifted from "sugar control" to both "sugar control" and "heart protection". GLP-1R agonists can improve left ventricular ejection fraction, myocardial contractility, coronary blood flow, cardiac output, and endothelial function while reducing infarction size and overall risks for a cardiovascular event. Other functions of GLP-1 include increased glucose uptake in the muscles, decreased glucose production in the liver, neuroprotection, and increased satiety due to direct actions on the hypothalamus. At present, the therapeutic application and potential value of GLP-1RAs in diabetes has become a research hotspot. In the formulation of GLP-1 integrated research plan, Medicilon has in-depth comm

  Medicilon, a one-stop pharmaceutical preclinical R&D service platform CRO, recognizes the importance of drug discovery as the cornerstone of new drug innovation. With extensive expertise in modern synthetic chemistry, Medicilon excels in various cutting-edge areas of pharmaceutical research, including chiral drugs, glycochemistry, antibodies and antibody-drug conjugates (ADC), nucleoside/nucleotide drugs, and oligonucleotide drugs (such as RNAi). Additionally, Medicilon has made significant advancements in PROTAC technology and established a progressively improved BSL-2 laboratory facility. With the development of the pharmaceutical industry and the widespread adoption of artificial intelligence, the market potential for drug discovery is enormous. The addition of Dr. Liu Jian, a seasoned pharmaceutical research scientist, will empower Medicilon  Drug Discovery  division to revolutionize drug discovery model and bring new imagination to new drug discovery and development. Recentl

  On June 3, 2023, the 25th annual conference of SAPA-NE (Sino-American Pharmaceutical Professionals Association–New England/Boston) was successfully held in Boston, MA. Dr. Chunlin Chen, CEO of Medicilon, Dr. Zhenrong Guo, Executive Vice President of Pharmaceutical Research, and the Medicilon US team attended the annual conference and had pleasant and in-depth exchanges with many guests and experts during the conference. With professional quality, confident demeanor, and exhibitions as a platform, Medicilon fully demonstrates and delivers the values of "focus on innovation, win-win collaboration, client first, and loving and dedication". During the conference, the Medicilon team conducted in-depth exchanges with a lot of pharmaceutical colleagues, and discussed about the industry situation and market prospects. From left to right: Cindy Chen, Dr. Jun Li, Dr. Chunlin Chen, Dr. Zhenrong Guo, Dr. Yan Zhou Dr. Chunlin Chen of Medicilon was invited to give a wonderful speech on &

  On June 16, 2023, the "2023 Chinese Pharmaceutical CRO Enterprise Ranking" was released and grandly awarded at the "2023 Conference on High Quality Development of Healthcare Industry & the Eight Summit for China Pharmaceutical R&D Innovation"!  Shanghai Medicilon Inc. was once again shortlisted for the 2023 China Pharmaceutical CRO Enterprise Ranking List. This is also the 4th consecutive year that Medicilon has won this honor! The selection of "Top 20 Chinese R&D CRO Enterprises in 2023" list is strictly based on the 10 indicators such as company's annual total revenue, annual revenue growth, net profit, net profit growth, R&D investment, R&D investment growth, number of employees, number of employees growth, brand popularity and leader in subdivided fields.  The list represents the highest level of  China's pharmaceutical CRO/CDMO industry .